We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

002380:KRXKCC Corporation Analysis

Data as of 2026-07-25 - not real-time

₩421,500.00

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

KCC Corp. is trading at KRW 421,500, well above its DCF‑derived fair value of roughly KRW 282,000, indicating an overvalued pricing environment. The forward P/E of 6.56 and a dividend yield of 3.56 % with a modest payout ratio of 6.5 % suggest the dividend is sustainable given strong operating cash flow and free cash flow. However, the company carries a high debt load (debt‑to‑equity ≈ 69) despite a solid cash position, which adds balance‑sheet stress. Technical signals are mixed: price sits below the 20‑day SMA (449,750) and 50‑day SMA (498,540), volume is on a decreasing trend, RSI is at 41 (neither overbought nor oversold), while the MACD histogram is marginally positive, hinting at limited short‑term upside. The market sentiment is extremely bullish (Fear‑Greed Index 88), yet volatility remains high at over 70 % for the past 30 days, and the beta exceeds 1, pointing to heightened systematic risk.
Given these dynamics, the stock appears overvalued on a price basis but underpinned by a reliable dividend and decent cash generation, making it a potential value play for patient investors while short‑term traders may prefer to stay on the sidelines.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Current price exceeds DCF fair value
  • Decreasing trading volume
  • Neutral technical trend with price below short‑term moving averages

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Sustainable dividend with low payout ratio
  • Strong operating and free cash flow
  • High debt level may limit upside

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Attractive dividend yield and cash generation
  • Potential for balance‑sheet deleveraging
  • Value orientation despite short‑term overvaluation

Key Metrics & Analysis

Financial Health

Revenue Growth1.70%
Profit Margin26.28%
P/E Ratio6.6
ROE23.84%
ROA1.43%
Debt/Equity69.42
Op. Cash Flow₩765.5B
Free Cash Flow₩449.1B

Technical Analysis

TrendNeutral
RSI41.2
Support₩383,000.00
Resistance₩526,000.00
MA 20₩449,750.00
MA 50₩498,540.00
MA 200₩478,747.50
MACDBullish
VolumeDecreasing
Fear & Greed Index88.25

Valuation

Fair Value₩282,319.99
Target Price₩676,400.00
Upside/Downside60.47%
GradeOvervalued
TypeValue
Dividend Yield3.56%

Risk Assessment

Beta1.30
Volatility71.30%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.